BACKGROUND: Precursor B-acute lymphoblastic leukemia occurring in patients with a history of malignancies is uncommon, and this condition is not well understood. DESIGN AND METHODS: A retrospective review of 457 adults with precursor B-acute lymphoblastic leukemia treated at our hospital identified 44 (9.6%) patients with prior malignancies. The clinical and genetic characteristics of this group of patients was compared with those of their counterparts with de novo disease and the relationship with prior chemoradiation therapy was assessed. RESULTS: Thirty of 44(6.2%) patients received cytotoxic therapies, whereas 14 patients did not. The former group showed a significantly shorter interval from prior malignancy to onset of precursor B-acute lymphoblastic leukemia (36 versus 144 months; P = 0.002). Compared with 413 de novo cases, the frequencies of t(4;11)(q21;q23) (P<0.001) and hypodiploidy (P = 0.009) with loss of chromosome 5, 7 or 17 were significantly higher in patients who received topoisomerase II inhibitor and/or alkylating agents. By contrast, Philadelphia-positive and normal karyotype were more frequent in patients who either did not receive chemotherapy or received only local radiation or nucleoside analogs. Patients with precursor B-acute lymphoblastic leukemia following prior malignancies and chemoradiation were older, had a lower complete remission rate and showed an inferior survival in univariate, but not multivariate analysis. CONCLUSIONS: The data support the interpretation that therapy-related precursor B-acute lymphoblastic leukemia does occur. In particular, cases associated with t(4;11)(q21;q23) or hypodiploidy with -5, -7, -17 are likely to be therapy-related and have a poor prognosis. The inferior outcome of these patients may be attributable to the high-risk cytogenetic abnormalities that are found in this group of patients.
BACKGROUND: Precursor B-acute lymphoblastic leukemia occurring in patients with a history of malignancies is uncommon, and this condition is not well understood. DESIGN AND METHODS: A retrospective review of 457 adults with precursor B-acute lymphoblastic leukemia treated at our hospital identified 44 (9.6%) patients with prior malignancies. The clinical and genetic characteristics of this group of patients was compared with those of their counterparts with de novo disease and the relationship with prior chemoradiation therapy was assessed. RESULTS: Thirty of 44(6.2%) patients received cytotoxic therapies, whereas 14 patients did not. The former group showed a significantly shorter interval from prior malignancy to onset of precursor B-acute lymphoblastic leukemia (36 versus 144 months; P = 0.002). Compared with 413 de novo cases, the frequencies of t(4;11)(q21;q23) (P<0.001) and hypodiploidy (P = 0.009) with loss of chromosome 5, 7 or 17 were significantly higher in patients who received topoisomerase II inhibitor and/or alkylating agents. By contrast, Philadelphia-positive and normal karyotype were more frequent in patients who either did not receive chemotherapy or received only local radiation or nucleoside analogs. Patients with precursor B-acute lymphoblastic leukemia following prior malignancies and chemoradiation were older, had a lower complete remission rate and showed an inferior survival in univariate, but not multivariate analysis. CONCLUSIONS: The data support the interpretation that therapy-related precursor B-acute lymphoblastic leukemia does occur. In particular, cases associated with t(4;11)(q21;q23) or hypodiploidy with -5, -7, -17 are likely to be therapy-related and have a poor prognosis. The inferior outcome of these patients may be attributable to the high-risk cytogenetic abnormalities that are found in this group of patients.
Authors: B D Lovett; L Lo Nigro; E F Rappaport; I A Blair; N Osheroff; N Zheng; M D Megonigal; W R Williams; P C Nowell; C A Felix Journal: Proc Natl Acad Sci U S A Date: 2001-08-07 Impact factor: 11.205
Authors: L Pagano; A Pulsoni; M E Tosti; L Annino; A Mele; A Camera; B Martino; C Guglielmi; R Cerri; E Di Bona; R Invernizzi; C Castagnola; R Bassan; L Mele; G Todeschini; G Leone; F Mandelli Journal: Br J Haematol Date: 1999-09 Impact factor: 6.998
Authors: Hagop Kantarjian; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich Journal: Cancer Date: 2004-12-15 Impact factor: 6.860
Authors: Vicki A Morrison; Kanti R Rai; Bercedis L Peterson; Jonathan E Kolitz; Laurence Elias; Frederick R Appelbaum; John D Hines; Lois Shepherd; Richard A Larson; Charles A Schiffer Journal: J Clin Oncol Date: 2002-09-15 Impact factor: 44.544
Authors: M J Keating; S O'Brien; S Lerner; C Koller; M Beran; L E Robertson; E J Freireich; E Estey; H Kantarjian Journal: Blood Date: 1998-08-15 Impact factor: 22.113
Authors: S Ishizawa; M L Slovak; L Popplewell; V Bedell; J E Wrede; N H Carter; D S Snyder; D A Arber Journal: Leukemia Date: 2003-06 Impact factor: 11.528
Authors: N A Heerema; J B Nachman; H N Sather; M K La; R Hutchinson; B J Lange; B Bostrom; P G Steinherz; P S Gaynon; F M Uckun Journal: Leukemia Date: 2004-05 Impact factor: 11.528
Authors: Valentina Nardi; Karen M Winkfield; Chi Young Ok; Andrzej Niemierko; Michael J Kluk; Eyal C Attar; Guillermo Garcia-Manero; Sa A Wang; Robert P Hasserjian Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Francesca Ferraro; Feng Gao; Keith Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Armin Ghobadi Journal: Leuk Res Date: 2018-07-31 Impact factor: 3.156
Authors: Brianna R Murphy; Michael Roth; E Anders Kolb; Todd Alonzo; Robert Gerbing; Robert J Wells Journal: Pediatr Blood Cancer Date: 2019-03-25 Impact factor: 3.167
Authors: Stephanie L Holdener; Lacey Harrington; Johnny Nguyen; Pedro Horna; Elizabeth Sagatys; Bijal Shah; Ling Zhang Journal: Int J Clin Exp Pathol Date: 2014-03-15
Authors: Caner Saygin; Ashwin Kishtagari; Ryan D Cassaday; Natalie Reizine; Ilana Yurkiewicz; Michaela Liedtke; Wendy Stock; Richard A Larson; Ross L Levine; Martin S Tallman; Jae H Park; Cassandra Kerr; Bartlomiej Przychodzen; Mikkael A Sekeres; Matt E Kalaycio; Hetty E Carraway; Betty K Hamilton; Ronald Sobecks; Aaron Gerds; Sudipto Mukherjee; Aziz Nazha; Jaroslaw P Maciejewski; Anjali S Advani Journal: Blood Adv Date: 2019-12-23